Core Viewpoint - The announcement details a significant ownership change in Chengzhi Co., with the indirect controlling shareholder, Qingdao Haikong Investment Holdings Co., transferring 100% of its shares in Chengzhi to its wholly-owned subsidiary, Dongjiakou Group, which will indirectly acquire 30.83% of Chengzhi's shares [1][2]. Group 1: Ownership Change - Dongjiakou Group has signed an agreement to acquire 100% of Qingdao Haikong Investment Holdings Co. without any monetary compensation, only incurring necessary fees as per national regulations [2]. - Prior to this acquisition, Dongjiakou Group did not hold any shares in Chengzhi, while Chengzhi Kairong, the current controlling shareholder, holds 375 million shares, representing 30.83% of the total share capital [1][2]. Group 2: Business Operations - Chengzhi Co. operates in industrial gases, basic chemical raw materials, semiconductor display materials, life science products, and industrial hemp cultivation and processing [2]. - The company reported a revenue of 11.066 billion yuan and a net profit of 231 million yuan for the fiscal year 2024, marking a year-on-year increase of 29.98% [2]. Group 3: Strategic Integration - The acquisition aims to promote internal strategic integration within Haikong Group, transferring ownership of Haikong Investment Holdings to Dongjiakou Group [1][2]. - There is no indication of competitive conflict between the businesses of the acquirer and Chengzhi, ensuring no adverse effects on the company's operations or minority shareholders [3].

【环球网财经综合报道】2025年5月22日，诚志股份云南地区公司与清华大学、云南省科学技术院、云南省农业科学院经济作物研究所、大理大学、昆明学 院、森瑞斯生物科技（深圳）有限公司等多家科研院所及企业分别签署了合作协议。清华大学化学工程系党委书记吕阳成，云南省科学技术院副院长李常 有，云南省农科院经济作物研究所党委书记马兴武，云南滇中新区人力资源开发中心主任樊泽俊，大理大学药学院院长张成桂，昆明学院农业与生命科学学 院党委书记刘开庆，森瑞斯生物科技（深圳）有限公司总裁周希彬，诚志股份有限公司董事、总裁韦俊民，云南诚志伟清生物科技有限公司（以下简称"诚 志伟清生物"）总经理刘大勇，云南汉盟制药有限公司（以下简称"诚志汉盟制药"）董事长熊华荣等出席仪式。 本次合作聚焦云南生物多样性开发和工业大麻综合开发利用，围绕技术研发、生物合成、人才培养、成果转化、市场拓展等多个领域开展深度合作，旨在整 合高校、科研院所与企业的优势资源，形成"育种种植-基础研究-应用开发-产业转化"全链条协同。通过政产学研深度融合，共同突破工业大麻全产业链技术 瓶颈，推动云南特色生物资源的高值化开发，为"诚志股份2.0版"战略在云南的落地提供核 ...

IM Cannabis (IMCC) Q1 2025 Earnings Call May 15, 2025 09:00 AM ET Company Participants Anna Taranko - Director - Investor & Public RelationsOren Shuster - CEO & ChairmanUri Birenberg - Chief Financial Officer Conference Call Participants None - Analyst Operator Good morning, and welcome to I'm Cannabis' First Quarter twenty twenty five Earnings Conference Call. Today's conference call is being recorded. At this time, I would like to turn the conference over to Anna Taranko, Director of Investor and public r ...

Financial Data and Key Metrics Changes - In Q1 2025, the company achieved a net profit with an 87% improvement in gross margin compared to Q1 2024 [5] - Adjusted EBITDA in Q1 2025 resulted in a profit of $600,000, an improvement of almost $3,000,000 from an adjusted EBITDA loss of $2,200,000 in Q1 2024 [8] - Revenues for Q1 2025 were $12,500,000, a 4% increase from $12,100,000 in Q1 2024, primarily driven by growth in Germany [8][10] - Gross profit for Q1 2025 was $3,400,000, a 94% increase from $1,800,000 in Q1 2024 [10] - Net profit for Q1 2025 was approximately $200,000, compared to a loss of $6,000,000 in Q1 2024, marking a $6,200,000 improvement [11] Business Line Data and Key Metrics Changes - The German business grew by 569% compared to Q1 2024, significantly offsetting a 66% revenue decline in Israel [6][8] - The company launched 12 new strains in Germany, contributing approximately €3,000,000 or 39% of cannabis flower sales in that market [5] - The decline in Israeli revenue was attributed to the cancellation of the Orenin deal, resulting in a decrease of approximately $3,500,000 compared to Q1 2024 [9] Market Data and Key Metrics Changes - Germany's share of total revenue in Q1 2025 increased to 62%, reflecting favorable market conditions and growing demand [9] - The cost of revenue decreased by 12% to $9,100,000 in Q1 2025, down from $10,300,000 in Q1 2024 [9] Company Strategy and Development Direction - The company is focusing on execution and resource allocation to areas with the highest return on investment (ROI) [5] - The strategic shift towards the German market is evident, with significant growth in that region while managing operational efficiencies [6][8] Management's Comments on Operating Environment and Future Outlook - Management expressed pride in the team's efforts and noted that the efficiencies and integration from the past two years are starting to reflect in financial results [6][11] - The company aims to continue executing its strategy and maintain profitability moving forward [7] Other Important Information - Total assets as of March 31, 2025, were $44,934,000, an increase of 15% from $39,188,000 as of December 31, 2024 [11] - Total liabilities increased by 16% to $41,761,000 as of March 31, 2025, compared to $36,042,000 as of December 31, 2024 [12] Q&A Session Summary Question: Importance of the upcoming meeting for accepting 25% ownership of Focus - Management indicated that this is a long process on the regulatory side and is crucial for clearing balances between companies and moving long-term loans to equity [17][18] - The need to hold 100% of the Focus shares is based on tax regulations to avoid issues with tax authorities [19]